Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Panel Recommends Authorization of Pfizer/BioNTech COVID-19 Vaccine for Kids Aged 5 to 11, Says Reuters

10/26/2021 | 05:39pm EST


© MT Newswires 2021
All news about PFIZER, INC.
04:52pFDA warns of increased heart-related issues from Pfizer's Xeljanz
RE
04:52pHealth Care Ticks Lower As Pfizer Gains - Health Care Roundup
DJ
04:02pPFIZER : FDA Issues Update to XELJANZ® Prescribing Information in the United States
PU
03:25pU.S. administers 466.3 mln doses of COVID-19 vaccines - CDC
RE
02:35pMerck to supply up to 1 mln courses of COVID-19 pill to Canada
RE
01:49pCanada Signs Deal for 1 Mln Doses of Pfizer Covid Antiviral and 500K Merck's Covid Pill
MT
12:15pVaccine makers could make Omicron-specific booster, says Fauci
RE
09:05aBioNTech Capable of Quickly Modifying Vaccine for Omicron Variant, CEO Says
MT
06:42aBioNTech CEO Expects To Modify COVID-19 Vaccine To Omicron Variant
MT
03:32aMalaysia Confirms First Case of New COVID-19 Variant
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 517 M - -
Net income 2021 21 354 M - -
Net Debt 2021 27 873 M - -
P/E ratio 2021 13,6x
Yield 2021 2,97%
Capitalization 298 B 298 B -
EV / Sales 2021 3,99x
EV / Sales 2022 3,76x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 53,04 $
Average target price 49,58 $
Spread / Average Target -6,53%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.44.09%297 706
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726
ABBVIE INC.8.18%206 612